174 participants
A Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of SB35 (Proposed Ixekizumab Biosimilar) to Taltz in Healthy Participants
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-27
- Start Date:
- 2026-09-02
- Completion:
- 2027-06-09
Conditions
- Healthy
Interventions
- DRUG
No Results Yet